PATENT CLAIM ANALYSIS

Application Number: 15868391
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["424", "172100"]

Abstract:
Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Claim (Index 4):
The method of  claim 3 , wherein the second RAR active agent is a RAR\u03b1 selective antagonist that is:\n a compound of general formula (I) \n wherein R 1 , R 2 , R 3 , and R 6  are independently H or C 1-6  alkyl; R 4  and R 5  are independently H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is C(CH 3 ) 2 , O, S, or NR 7 , wherein R 7  is H or C 1-6  alkyl; X 1  is H or halogen such as F, Cl or Br; and R 8  is H or OH; (ii) a compound of general formula (II) wherein R 1  and R 2  are independently C 1-6  alkyl; X is O, S, or CH 2 ; Y is O, S, CH 2 , or NR 3 , wherein R 3  is C 1-6  alkyl; Z is Cl or Br; W is H or OH; and U is independently H or F; (iii) a compound of general formula (III) wherein R 1  and R 2  are independently H or C 1-6  alkyl; R 3  is H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is O, S, N, or CH 2 ; W is H or OH; and Z is Cl or Br; or (iv) BMS185411, BMS614, Ro41-5253, or Ro46-5471.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 86.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15620411', '15868459', '15868450', '15868469', '14507730']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8193485007421725
- 35 USC 102 Novelty (BERT): 0.6242198679313417
- Combined Prediction Score: 0.7998356374610894
- Mean Citation Score: 509.35826
- Max Citation Score: 577.6576
- Similarity Product: 543.26570651474

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test